ea0056p140 | Endocrine tumours and neoplasia | ECE2018
Bakhit Mohamed
, Whitelaw Benjamin C
, Gilbert Jackie
, Coskeran Patsy
, Diaz-Cano Salvador
, Taylor David R
, Taylor Norman T
, Ghatore Lea
, Lewis Dylan
, Vivian Gillian
, Sarker Debashis
, Ross Paul
, Davis Laura May
, Clough Jennifer
, Hubbard Johnathan G
, Galata Gabriele
, Prachalias Andreas
, Schulte Klaus-Martin
, Aylwin Simon J B
Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).Methods: Review of patients presenti...